Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
24.9M
-
Shares change
-
+582K
-
Total reported value, excl. options
-
$1.48B
-
Value change
-
+$46.3M
-
Put/Call ratio
-
0.76
-
Number of buys
-
90
-
Number of sells
-
-53
-
Price
-
$59.63
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2019
206 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2019.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.9M shares
of 207M outstanding shares and own 11.98% of the company stock.
Largest 10 shareholders include Bellevue Group AG (4.53M shares), VANGUARD GROUP INC (2.65M shares), Pentwater Capital Management LP (2.25M shares), BlackRock Inc. (2.07M shares), STATE STREET CORP (1.1M shares), BOXER CAPITAL, LLC (975K shares), CREDIT SUISSE AG/ (888K shares), WASATCH ADVISORS INC (665K shares), Rhenman & Partners Asset Management AB (660K shares), and NOMURA HOLDINGS INC (550K shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.